Fludarabine phosphate
Fludarabine phosphate structure
|
Common Name | Fludarabine phosphate | ||
|---|---|---|---|---|
| CAS Number | 75607-67-9 | Molecular Weight | 365.212 | |
| Density | 2.4±0.1 g/cm3 | Boiling Point | 864.2±75.0 °C at 760 mmHg | |
| Molecular Formula | C10H13FN5O7P | Melting Point | 203 °C(dec.) | |
| MSDS | N/A | Flash Point | 476.4±37.1 °C | |
|
Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration.
Cancer Chemother. Pharmacol. 75(1) , 67-75, (2015) Quantitative relationships between 9-β-D-arabinofuranosyl-2-fluoroadenine (F-ara-A) concentrations and lymphosuppression have not been reported, but would be useful for regimen design. A population pharmacokinetic/pharmacodynamic model was constructed in this... |
|
|
Fludarabine phosphate in lymphoma: an important new therapeutic agent.
Cancer Treat. Res. 85 , 3-14, (1996)
|
|
|
Fludarabine phosphate in the treatment of chronic lymphocytic leukemia: biology, clinical impact, and future directions.
Cancer Treat. Res. 64 , 105-19, (1993)
|
|
|
Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies.
J. Clin. Oncol. 9(1) , 175-88, (1991) Fludarabine phosphate is the 2-fluoro, 5'-monophosphate derivative of vidarabine (ara-A) with the advantages of resistance to deamination by adenosine deaminase (ADA) and improved solubility. The mechanism of cytotoxic action of the compound appears to involv... |
|
|
Metabolism and action of fludarabine phosphate.
Semin. Oncol. 17(5 Suppl 8) , 3-17, (1990) Fludara I.V. (fludarabine phosphate) (9-beta-D-arabinosyl-2-fluoroadenine, F-ara-A) is an adenine nucleoside analogue resistant to adenosine deaminase that shows promising therapeutic activity in the clinical treatment of lymphocytic hematologic malignancies.... |
|
|
Fludarabine phosphate in the treatment of chronic lymphocytic leukemia.
Semin. Oncol. 17(5 Suppl 8) , 49-62, (1990) Fludara I.V. (fludarabine phosphate) is a purine analogue that has been synthesized and found to have activity in lymphoid neoplasms in phase I and II studies. Fludara I.V. has been used extensively in the management of chronic lymphocytic leukemia in the las... |
|
|
Fludarabine phosphate therapy in other lymphoid malignancies.
Semin. Oncol. 17(5 Suppl 8) , 66-70, (1990) The promising results obtained with Fludara I.V. (fludarabine phosphate) treatment in the common indolent B-cell neoplasms have led to their further evaluation in other unusual B-cell malignancies, in Hodgkin's disease, and in T-cell diseases. A significant r... |
|
|
Phase I clinical trials with fludarabine phosphate.
Semin. Oncol. 17(5 Suppl 8) , 33-8, (1990) There have been six different phase I trials of Fludara I.V. (fludarabine phosphate) in patients with solid tumors and three different phase I trials of Fludara I.V. in patients with acute leukemia. In addition, one trial of the agent given intraperitoneally ... |
|
|
Fludarabine phosphate in chronic lymphoproliferative diseases. The French Group on CLL.
Nouv. Rev. Fr. Hematol. 35(1) , 5-7, (1993) The review of Phase II trials in patients treated by Fludarabine phosphate (Fludara I.V) has been demonstrated to have unequivocal benefit for some patients with Chronic Lymphocytic Leukemia (CLL) non Hodgkin lymphoma and macroglobulinemia. Comparison of Flud... |
|
|
Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma.
Invest. New Drugs 12(2) , 75-92, (1994) Fludarabine phosphate is a purine antimetabolite approved for use in the management of patients with chronic lymphocytic leukemia. Fludarabine works primarily by inhibiting DNA synthesis. The compound also possesses lymphocytotoxic activity with preferential ... |